Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Spinal Underwear May Relieve Lower Back Pain

Lara C. Pullen, PhD  |  March 14, 2017

A recent study in nurses and healthcare professionals examined the efficacy of a novel ergonomic aid for managing low back pain. After a three-month trial, researchers found that the aid, Spinal Underwear, reduced low back pain, suggesting that musculoskeletal symptoms may be influenced by posture and somatization…

Filed under:ConditionsResearch Rheum Tagged with:Association of Rheumatology Professionals (ARP)Back painlow back painMusculoskeletal

U.S. Doctors in Training to Work Longer Hours Under New Guidelines

Andrew M. Seaman  |  March 13, 2017

(Reuters Health)—Days may get a lot longer for some doctors in training after the group that oversees medical education in the U.S. rolled back controversial rules limiting the number of hours first-year residents may work. Beginning July 1, doctors in their first year of training after medical school may once again care for patients for…

Filed under:Career DevelopmentEducation & TrainingProfessional Topics Tagged with:ACGMEmedical education

Brodalumab Approved for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  March 9, 2017

Brodalumab has received FDA approval for treating plaque psoriasis in adults, with a Boxed Warning against prescribing it for patients with a history of suicidal thoughts or behavior…

Filed under:Biologics/DMARDsDrug Updates Tagged with:brodalumabFDAFood and Drug Administrationplaque psoriasis

Moderate Alcohol Intake Decreases SLE Risk in Women

Arthritis Care & Research  |  March 8, 2017

Beer, wine, liquor—alcohol contains elements that suppress systemic inflammation, and its consumption has been linked to reduced risk of cardiovascular disease and RA. A recent analysis examined the effect of alcohol on SLE risk in women from the two Nurses’ Health Study cohorts. The results: Researchers found an inverse association between moderate alcohol consumption and SLE risk—with a 39% reduction in SLE risk among women who consumed about half a drink of alcohol daily…

Filed under:ConditionsSystemic Lupus Erythematosus

U.S. Republicans Unveil Plan to Dismantle Obamacare, Critics Pounce

Susan Cornwell & Yasmeen Abutaleb  |  March 7, 2017

WASHINGTON (Reuters)—Long-awaited legislation to dismantle Obamacare was unwrapped on Monday by U.S. Republicans, who called for ending health insurance mandates and rolling back extra healthcare funding for the poor in a package that drew immediate fire from Democrats. In a battle waged since the 2010 passage of the Affordable Care Act, Democratic President Barack Obama’s…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Affordable Care Act (ACA)Health InsuranceObamacarePatient Protection and Affordable Care Act

Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA

Michele B. Kaufman, PharmD, BCGP  |  March 7, 2017

In a recent study, baricitinib proved more effective than adalimumab in treating adults with RA through 52 weeks…

Filed under:Drug Updates Tagged with:baricitinibRheumatoid Arthritis (RA)

What Rheumatologists Wish Their Colleagues Knew: Managing Skin Disease & Comorbidities

Richard Quinn  |  March 3, 2017

From treating rashes to uncovering a case of osteoarthritis, dermatologists and rheumatologists can work together in a variety of ways to improve patient care, says Joseph F. Merola, MD, MMSc…

Filed under:ConditionsPsoriatic ArthritisSystemic Sclerosis Tagged with:DermatologyPsoriasisPsoriatic Arthritisrheumatologistskinskin disease

ACR Releases New Position Statements on Site of Service & Compounding

Mary Beth Nierengarten  |  March 1, 2017

Patient Safety & Site of Service for Biologics Although emphasizing its strong support for the use of biologic agents as necessary treatments for rheumatic diseases, the ACR Board of Directors continues to be concerned about the safe delivery of these agents, given the potential for associated adverse events and infusion reactions. In a position statement…

Filed under:Biologics/DMARDsLegislation & Advocacy Tagged with:biologic infusionsdrug compoundingposition statementquinacrine

Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial

Michele B. Kaufman, PharmD, BCGP  |  March 1, 2017

Certolizumab pegol has proved safe and effective for treating patients with plaque psoriasis in a Phase 3 clinical trial…

Filed under:Biologics/DMARDsConditionsDrug UpdatesSystemic Sclerosis Tagged with:Certolizumab Pegoletanerceptplaque psoriasis

FDA Considers Tocilizumab for GCA & Piclidenoson Enters Phase 3 Trial for RA, Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  February 27, 2017

The FDA is considering a supplemental biologics license application for tocilizumab to treat giant cell arteritis…

Filed under:Biologics/DMARDsDrug Updates Tagged with:FDAFood and Drug AdministrationGCAgiant cell arteritis (GCA)piclidenosontocilizumab

  • « Previous Page
  • 1
  • …
  • 190
  • 191
  • 192
  • 193
  • 194
  • …
  • 324
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences